In this issue:
Retrospective study of with t(14;16) MM
RVD + daratumumab in transplant-eligible newly diagnosed MM
Associations with OS in NZ MM patients
VTE risk with lenalidomide regimens for MM despite thromboprophylaxis
Factors predicting MM outcomes at different ages
Significance of dysplastic haematopoiesis in newly diagnosed MM
The genomic and transcriptomic landscape of double-refractory MM
An anti-BCMA BITE induces responses in MM
First-line VMP vs. Rd-R for transplant-ineligible MM
Ibrutinib, bortezomib and dexamethasone in relapsed/refractory MM
Download PDF